以岭药业以创新与社会责任诠释领军担当荣获“年度医药行业领军企业”

Core Viewpoint - Yiling Pharmaceutical exemplifies the concept of "health new trend, value co-existence" through its unique model integrating theory, clinical practice, research, industry, and education, while being recognized as the "Leading Enterprise in the Pharmaceutical Industry" in the 2025 New Consumption and New Economy Awards by Caijing [1] Group 1: Market Position and Recognition - The recognition of Yiling Pharmaceutical's market position and research strength reflects its commitment to integrating corporate development into the grand narrative of "Healthy China" and fulfilling social responsibilities through concrete actions [3] Group 2: Research and Development Investment - In the first three quarters of 2025, the company's R&D investment reached 544 million yuan, accounting for 9.27% of its revenue, continuing to lead the industry [3] - Cumulatively, from 2019 to 2024, the total R&D investment has exceeded 5 billion yuan, creating a virtuous cycle of "investment-transformation-reinvestment" [3] Group 3: Product Development and Social Impact - The company's high-intensity, long-term investment aims to develop "Chinese medicine" that aligns with the genetic and physical characteristics of the Chinese population, resulting in 17 patented traditional Chinese medicines covering major diseases such as cardiovascular, respiratory, and tumors [4] - By 2025, the new traditional Chinese medicine "Qifang Nasal Tablets" was approved for listing and successfully entered the Macau market, becoming the first registered innovative traditional Chinese medicine in Macau [4] - Among the 17 patented traditional Chinese medicines, 12 have been included in the national medical insurance catalog, and 5 have entered the national essential medicines list, significantly reducing the economic burden of diseases for ordinary patients [4] Group 4: Scientific Research and Global Recognition - The company has conducted over 40 evidence-based medical studies, establishing a research evidence system that integrates traditional Chinese and Western medicine, with results published in top international journals such as JAMA and Nature Medicine [5] - This commitment to rigorous data and scientific methods provides a "passport" for the effectiveness of traditional Chinese medicine recognized by the global medical community [5] Group 5: Responsibility and Future Vision - Yiling Pharmaceutical's path of responsibility is evident from laboratory research data to the list of drugs in the medical insurance catalog and academic papers in international top journals, contributing positively to global health through Chinese wisdom [6] - The company's focus on developing good medicines and ensuring they serve the public reflects its dedication to social responsibility and the health of future generations [7]